HRP20150919T1 - Derivati 2-metoksi-piridin-4-ila - Google Patents
Derivati 2-metoksi-piridin-4-ila Download PDFInfo
- Publication number
- HRP20150919T1 HRP20150919T1 HRP20150919TT HRP20150919T HRP20150919T1 HR P20150919 T1 HRP20150919 T1 HR P20150919T1 HR P20150919T T HRP20150919T T HR P20150919TT HR P20150919 T HRP20150919 T HR P20150919T HR P20150919 T1 HRP20150919 T1 HR P20150919T1
- Authority
- HR
- Croatia
- Prior art keywords
- ethyl
- och2
- cyclopentyl
- oxadiazol
- och2ch
- Prior art date
Links
- -1 2-methoxy-pyridin-4-yl Chemical class 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 45
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 41
- 150000003839 salts Chemical class 0.000 claims 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 18
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 18
- 125000001309 chloro group Chemical group Cl* 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims 2
- 235000019260 propionic acid Nutrition 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000011476 stem cell transplantation Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- BSTXIGLLNAKTPM-QFIPXVFZSA-N (2s)-1-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-3-(2-hydroxyethylamino)propan-2-ol Chemical compound CC1=C(OC[C@@H](O)CNCCO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 BSTXIGLLNAKTPM-QFIPXVFZSA-N 0.000 claims 1
- CCCFDTGGBVEHLV-QFIPXVFZSA-N (2s)-1-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl]-2-ethyl-6-methylphenoxy]-3-(2-hydroxyethylamino)propan-2-ol Chemical compound CC1=C(OC[C@@H](O)CNCCO)C(CC)=CC(C=2OC(=NN=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 CCCFDTGGBVEHLV-QFIPXVFZSA-N 0.000 claims 1
- LXUDYKYQEFVRRP-QHCPKHFHSA-N 1-[(2s)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]azetidine-3-carboxylic acid Chemical compound C([C@H](O)COC1=C(C)C=C(C=C1CC)C=1N=C(ON=1)C=1C=C(N=C(OC)C=1)C1CCCC1)N1CC(C(O)=O)C1 LXUDYKYQEFVRRP-QHCPKHFHSA-N 0.000 claims 1
- PDWWVTGIZJWOSB-UHFFFAOYSA-N 1-[2-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methoxyphenoxy]ethyl]azetidine-3-carboxylic acid Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(OC)C(OCCN3CC(C3)C(O)=O)=C(Cl)C=2)=CC=1C1CCCC1 PDWWVTGIZJWOSB-UHFFFAOYSA-N 0.000 claims 1
- LSAMTFCFKVYGRC-UHFFFAOYSA-N 1-[2-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]ethyl]azetidine-3-carboxylic acid Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(Cl)C(OCCN3CC(C3)C(O)=O)=C(C)C=2)=CC=1C1CCCC1 LSAMTFCFKVYGRC-UHFFFAOYSA-N 0.000 claims 1
- HKGBHVJBMBLWGS-UHFFFAOYSA-N 1-[2-[4-[3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl]-2-ethyl-6-methylphenoxy]ethyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C=2ON=C(N=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=CC(C)=C1OCCN1CC(C(O)=O)C1 HKGBHVJBMBLWGS-UHFFFAOYSA-N 0.000 claims 1
- ZZYJBJHRUCBFFW-UHFFFAOYSA-N 1-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=CC(C)=C1OCCN1CC(C(O)=O)C1 ZZYJBJHRUCBFFW-UHFFFAOYSA-N 0.000 claims 1
- AGHIBBJTQTZHKO-UHFFFAOYSA-N 1-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethyl]pyrrolidine-3-carboxylic acid Chemical compound CCC1=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=CC(C)=C1OCCN1CCC(C(O)=O)C1 AGHIBBJTQTZHKO-UHFFFAOYSA-N 0.000 claims 1
- UZIZDCVCEKLHAO-UHFFFAOYSA-N 1-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl]-2-ethyl-6-methylphenoxy]ethyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C=2OC(=NN=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=CC(C)=C1OCCN1CC(C(O)=O)C1 UZIZDCVCEKLHAO-UHFFFAOYSA-N 0.000 claims 1
- AAFVYXKWZCNQIT-UHFFFAOYSA-N 1-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=CC(C)=C1OCCCN1CC(C(O)=O)C1 AAFVYXKWZCNQIT-UHFFFAOYSA-N 0.000 claims 1
- OQLZRZSIPUOHHH-UHFFFAOYSA-N 2-[2-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methoxyphenoxy]ethylamino]acetic acid Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(OC)C(OCCNCC(O)=O)=C(Cl)C=2)=CC=1C1CCCC1 OQLZRZSIPUOHHH-UHFFFAOYSA-N 0.000 claims 1
- UDSNJODEWBAOMV-UHFFFAOYSA-N 2-[2-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]ethylamino]ethanol Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(Cl)C(OCCNCCO)=C(C)C=2)=CC=1C1CCCC1 UDSNJODEWBAOMV-UHFFFAOYSA-N 0.000 claims 1
- YILKRDJBANPMMY-UHFFFAOYSA-N 2-[2-[4-[3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl]-2-ethyl-6-methylphenoxy]ethyl-methylamino]acetic acid Chemical compound CC1=C(OCCN(C)CC(O)=O)C(CC)=CC(C=2ON=C(N=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 YILKRDJBANPMMY-UHFFFAOYSA-N 0.000 claims 1
- BPYABSLUNZREGY-UHFFFAOYSA-N 2-[2-[4-[3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl]-2-ethyl-6-methylphenoxy]ethylamino]acetic acid Chemical compound CC1=C(OCCNCC(O)=O)C(CC)=CC(C=2ON=C(N=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 BPYABSLUNZREGY-UHFFFAOYSA-N 0.000 claims 1
- SAOTZFPYZKQKBP-UHFFFAOYSA-N 2-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethyl-methylamino]acetic acid Chemical compound CC1=C(OCCN(C)CC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 SAOTZFPYZKQKBP-UHFFFAOYSA-N 0.000 claims 1
- LSSBCKGEKZINPW-UHFFFAOYSA-N 2-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethylamino]acetic acid Chemical compound CC1=C(OCCNCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 LSSBCKGEKZINPW-UHFFFAOYSA-N 0.000 claims 1
- VMIQTOXOOURJPZ-UHFFFAOYSA-N 2-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethylamino]ethanol Chemical compound CC1=C(OCCNCCO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 VMIQTOXOOURJPZ-UHFFFAOYSA-N 0.000 claims 1
- QOJPXTFUHJEONC-UHFFFAOYSA-N 2-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethylamino]propane-1,3-diol Chemical compound CC1=C(OCCNC(CO)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 QOJPXTFUHJEONC-UHFFFAOYSA-N 0.000 claims 1
- KNIPBJUVGPEECD-UHFFFAOYSA-N 2-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]-n-(2-hydroxyethyl)acetamide Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(Cl)C(OCC(=O)NCCO)=C(C)C=2)=CC=1C1CCCC1 KNIPBJUVGPEECD-UHFFFAOYSA-N 0.000 claims 1
- UJGFZRQLHIGUGR-UHFFFAOYSA-N 2-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]acetic acid Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(Cl)C(OCC(O)=O)=C(C)C=2)=CC=1C1CCCC1 UJGFZRQLHIGUGR-UHFFFAOYSA-N 0.000 claims 1
- IGCJLENDBNKNKW-UHFFFAOYSA-N 2-[3-[4-[3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl]-2-ethyl-6-methylphenoxy]propylamino]acetic acid Chemical compound CC1=C(OCCCNCC(O)=O)C(CC)=CC(C=2ON=C(N=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 IGCJLENDBNKNKW-UHFFFAOYSA-N 0.000 claims 1
- PWJMMNNRWROWLV-UHFFFAOYSA-N 2-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propyl-methylamino]acetic acid Chemical compound CC1=C(OCCCN(C)CC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 PWJMMNNRWROWLV-UHFFFAOYSA-N 0.000 claims 1
- YWESWVZCUKWASR-UHFFFAOYSA-N 2-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propylamino]acetic acid Chemical compound CC1=C(OCCCNCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 YWESWVZCUKWASR-UHFFFAOYSA-N 0.000 claims 1
- WLZRJSBVIWCBDF-UHFFFAOYSA-N 2-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propylamino]ethanol Chemical compound CC1=C(OCCCNCCO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 WLZRJSBVIWCBDF-UHFFFAOYSA-N 0.000 claims 1
- PCINYICLWPRVPR-UHFFFAOYSA-N 2-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propylamino]propane-1,3-diol Chemical compound CC1=C(OCCCNC(CO)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 PCINYICLWPRVPR-UHFFFAOYSA-N 0.000 claims 1
- RLGHELIEZTXLHK-UHFFFAOYSA-N 2-[4-[3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl]-2-ethyl-6-methylphenoxy]acetic acid Chemical compound CC1=C(OCC(O)=O)C(CC)=CC(C=2ON=C(N=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 RLGHELIEZTXLHK-UHFFFAOYSA-N 0.000 claims 1
- RHIPIFYFDLRWGD-UHFFFAOYSA-N 2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-n-(2-hydroxyethyl)acetamide Chemical compound CC1=C(OCC(=O)NCCO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 RHIPIFYFDLRWGD-UHFFFAOYSA-N 0.000 claims 1
- YVLKKNHLZXEDRG-UHFFFAOYSA-N 2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]acetic acid Chemical compound CC1=C(OCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 YVLKKNHLZXEDRG-UHFFFAOYSA-N 0.000 claims 1
- OLOOTCSQBNGFDJ-UHFFFAOYSA-N 2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl]-2-ethyl-6-methylphenoxy]acetic acid Chemical compound CC1=C(OCC(O)=O)C(CC)=CC(C=2OC(=NN=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 OLOOTCSQBNGFDJ-UHFFFAOYSA-N 0.000 claims 1
- JYXBBHRKCXVUJT-QHCPKHFHSA-N 2-[[(2s)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]amino]propane-1,3-diol Chemical compound CC1=C(OC[C@@H](O)CNC(CO)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 JYXBBHRKCXVUJT-QHCPKHFHSA-N 0.000 claims 1
- SCTMWZYLKVFKAD-UHFFFAOYSA-N 3-[2-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methoxyphenoxy]ethylamino]propanoic acid Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(OC)C(OCCNCCC(O)=O)=C(Cl)C=2)=CC=1C1CCCC1 SCTMWZYLKVFKAD-UHFFFAOYSA-N 0.000 claims 1
- JEDKMJYIEPVASF-UHFFFAOYSA-N 3-[2-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]ethylamino]propanoic acid Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(Cl)C(OCCNCCC(O)=O)=C(C)C=2)=CC=1C1CCCC1 JEDKMJYIEPVASF-UHFFFAOYSA-N 0.000 claims 1
- YSZRYQAFFQVHCE-UHFFFAOYSA-N 3-[2-[4-[3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl]-2-ethyl-6-methylphenoxy]ethylamino]propanoic acid Chemical compound CC1=C(OCCNCCC(O)=O)C(CC)=CC(C=2ON=C(N=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 YSZRYQAFFQVHCE-UHFFFAOYSA-N 0.000 claims 1
- SGSGLMISXKYOLH-UHFFFAOYSA-N 3-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethyl-methylamino]propanoic acid Chemical compound CC1=C(OCCN(C)CCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 SGSGLMISXKYOLH-UHFFFAOYSA-N 0.000 claims 1
- DAMNEWHGJGROAD-UHFFFAOYSA-N 3-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethylamino]-3-oxopropanoic acid Chemical compound CC1=C(OCCNC(=O)CC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 DAMNEWHGJGROAD-UHFFFAOYSA-N 0.000 claims 1
- VIOKGRBDACOCKM-UHFFFAOYSA-N 3-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethylamino]propane-1,2-diol Chemical compound CC1=C(OCCNCC(O)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 VIOKGRBDACOCKM-UHFFFAOYSA-N 0.000 claims 1
- IFHXQKCQGDNVGP-UHFFFAOYSA-N 3-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethylamino]propanoic acid Chemical compound CC1=C(OCCNCCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 IFHXQKCQGDNVGP-UHFFFAOYSA-N 0.000 claims 1
- OADIQAYYSHHQIS-UHFFFAOYSA-N 3-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl]-2-ethyl-6-methylphenoxy]ethylamino]propanoic acid Chemical compound CC1=C(OCCNCCC(O)=O)C(CC)=CC(C=2OC(=NN=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 OADIQAYYSHHQIS-UHFFFAOYSA-N 0.000 claims 1
- YCMLWSYJGLZMDJ-UHFFFAOYSA-N 3-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propyl-methylamino]-3-oxopropanoic acid Chemical compound CC1=C(OCCCN(C)C(=O)CC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 YCMLWSYJGLZMDJ-UHFFFAOYSA-N 0.000 claims 1
- CSXSNVRAUMPAGA-UHFFFAOYSA-N 3-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propyl-methylamino]propanoic acid Chemical compound CC1=C(OCCCN(C)CCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 CSXSNVRAUMPAGA-UHFFFAOYSA-N 0.000 claims 1
- GANOKLNGAVHKOZ-UHFFFAOYSA-N 3-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propylamino]-3-oxopropanoic acid Chemical compound CC1=C(OCCCNC(=O)CC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 GANOKLNGAVHKOZ-UHFFFAOYSA-N 0.000 claims 1
- MRUJFVGKZYZUKZ-UHFFFAOYSA-N 3-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propylamino]propane-1,2-diol Chemical compound CC1=C(OCCCNCC(O)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 MRUJFVGKZYZUKZ-UHFFFAOYSA-N 0.000 claims 1
- TZDSHHNTAIIIIX-UHFFFAOYSA-N 3-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propylamino]propanoic acid Chemical compound CC1=C(OCCCNCCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 TZDSHHNTAIIIIX-UHFFFAOYSA-N 0.000 claims 1
- IHXOGVSFVUFTTG-NRFANRHFSA-N 3-[[(2s)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]amino]-3-oxopropanoic acid Chemical compound CC1=C(OC[C@@H](O)CNC(=O)CC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 IHXOGVSFVUFTTG-NRFANRHFSA-N 0.000 claims 1
- KBPCVZUCLXZSKB-QFIPXVFZSA-N 3-[[(2s)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]amino]propanoic acid Chemical compound CC1=C(OC[C@@H](O)CNCCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 KBPCVZUCLXZSKB-QFIPXVFZSA-N 0.000 claims 1
- IVEBEECOSQPFJC-UHFFFAOYSA-N 4-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethylamino]-4-oxobutanoic acid Chemical compound CC1=C(OCCNC(=O)CCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 IVEBEECOSQPFJC-UHFFFAOYSA-N 0.000 claims 1
- FRYVGUFGCKMTOM-UHFFFAOYSA-N 4-[2-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]ethylamino]butanoic acid Chemical compound CC1=C(OCCNCCCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 FRYVGUFGCKMTOM-UHFFFAOYSA-N 0.000 claims 1
- IKRAQJLSPMGCTA-UHFFFAOYSA-N 4-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methoxyphenoxy]-n-(2-hydroxyethyl)butanamide Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(OC)C(OCCCC(=O)NCCO)=C(Cl)C=2)=CC=1C1CCCC1 IKRAQJLSPMGCTA-UHFFFAOYSA-N 0.000 claims 1
- SRCXUXBIUMJXLC-UHFFFAOYSA-N 4-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methoxyphenoxy]butanoic acid Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(OC)C(OCCCC(O)=O)=C(Cl)C=2)=CC=1C1CCCC1 SRCXUXBIUMJXLC-UHFFFAOYSA-N 0.000 claims 1
- BGLMVHCSZFRBBF-UHFFFAOYSA-N 4-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]butanoic acid Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(Cl)C(OCCCC(O)=O)=C(C)C=2)=CC=1C1CCCC1 BGLMVHCSZFRBBF-UHFFFAOYSA-N 0.000 claims 1
- KFUSKIJKJMJJOH-UHFFFAOYSA-N 4-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propyl-methylamino]-4-oxobutanoic acid Chemical compound CC1=C(OCCCN(C)C(=O)CCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 KFUSKIJKJMJJOH-UHFFFAOYSA-N 0.000 claims 1
- WTWBLEMKKIKCIS-UHFFFAOYSA-N 4-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propylamino]-4-oxobutanoic acid Chemical compound CC1=C(OCCCNC(=O)CCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 WTWBLEMKKIKCIS-UHFFFAOYSA-N 0.000 claims 1
- JNIJAABTXYZLTJ-UHFFFAOYSA-N 4-[4-[3-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl]-2-ethyl-6-methylphenoxy]butanoic acid Chemical compound CC1=C(OCCCC(O)=O)C(CC)=CC(C=2ON=C(N=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 JNIJAABTXYZLTJ-UHFFFAOYSA-N 0.000 claims 1
- QANAHAVQWPJOQE-UHFFFAOYSA-N 4-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-n-(2-hydroxyethyl)butanamide Chemical compound CC1=C(OCCCC(=O)NCCO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 QANAHAVQWPJOQE-UHFFFAOYSA-N 0.000 claims 1
- XKHVADTXWIMEPM-UHFFFAOYSA-N 4-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]butanoic acid Chemical compound CC1=C(OCCCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 XKHVADTXWIMEPM-UHFFFAOYSA-N 0.000 claims 1
- XHQYPKRPCJSVJC-UHFFFAOYSA-N 4-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl]-2-ethyl-6-methylphenoxy]butanoic acid Chemical compound CC1=C(OCCCC(O)=O)C(CC)=CC(C=2OC(=NN=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 XHQYPKRPCJSVJC-UHFFFAOYSA-N 0.000 claims 1
- NAXUGDMYPSMXAQ-QFIPXVFZSA-N 4-[[(2s)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]amino]-4-oxobutanoic acid Chemical compound CC1=C(OC[C@@H](O)CNC(=O)CCC(O)=O)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 NAXUGDMYPSMXAQ-QFIPXVFZSA-N 0.000 claims 1
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- MALJKOUYAYUDAM-UHFFFAOYSA-N n-[3-[2-chloro-4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methoxyphenoxy]propyl]-2-hydroxyacetamide Chemical compound N=1C(OC)=CC(C=2ON=C(N=2)C=2C=C(OC)C(OCCCNC(=O)CO)=C(Cl)C=2)=CC=1C1CCCC1 MALJKOUYAYUDAM-UHFFFAOYSA-N 0.000 claims 1
- YUVOOLGBMLXGIQ-UHFFFAOYSA-N n-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propyl]-2-hydroxy-n-methylacetamide Chemical compound CC1=C(OCCCN(C)C(=O)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 YUVOOLGBMLXGIQ-UHFFFAOYSA-N 0.000 claims 1
- OMEVSHHVJPBFDK-UHFFFAOYSA-N n-[3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propyl]-2-hydroxyacetamide Chemical compound CC1=C(OCCCNC(=O)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 OMEVSHHVJPBFDK-UHFFFAOYSA-N 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Claims (25)
1. Spoj, naznačen time, da ima formulu (I),
[image]
gdje
A predstavlja
[image]
pri čemu zvjezdice označavaju vezu koja je spojena na piridin-skupinu formule (I);
R1 predstavlja ciklopentil;
R2 predstavlja metil, i R4 predstavlja etil ili kloro; ili
R2 predstavlja metoksi, i R4 predstavlja kloro;
R3 predstavlja:
-OCH2COOH, -OCH2CH2CH2COOH, -OCH2CONHCH2CH2OH,
-OCH2CH2CH2CONHCH2CH2OH, -OCH2-(CH2)n-NH-(CH2)m-COOH,
-OCH2-(CH2)n-N(CH3)-(CH2)m-COOH,
2-[(azetidin-3-karboksilna kiselina)-1-il]-etoksi,
2-[(pirolidin-3-karboksilna kiselina)-1-il]-etoksi,
3-[(azetidin-3-karboksilna kiselina)-1-il]-propoksi,
3-[(pirolidin-3-karboksilna kiselina)-1-il]-propoksi,
-OCH2CH(OH)-CH2NH-CH2COOH, -OCH2CH(OH)-CH2NH-CH2CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2CH2COOH,
3-[(azetidin-3-karboksilna kiselina)-1-il]-2-hidroksi-propoksi,
2-hidroksi-3-[(pirolidin-3-karboksilna kiselina)-1-il]-propoksi,
-OCH2-(CH2)n-NH-CH2CH2OH, -OCH2-(CH2)n-NH-CH(CH2OH)2,
-OCH2-(CH2)n-NH-CH2CH(OH)-CH2OH, -OCH2CH(OH)-CH2NH-CH2CH2OH,
-OCH2CH(OH)-CH2NH-CH(CH2OH)2, -OCH2-(CH2)k-NH-CO-CH2OH,
-OCH2-(CH2)n-NH-CO-CH2COOH, -OCH2-(CH2)n-NH-CO-CH2CH2COOH,
-OCH2CH(OH)-CH2NH-CO-(CH2)nCOOH,
-OCH2-(CH2)n-N(CH3)-CO-CH2OH,
-OCH2-(CH2)n-N(CH3)-CO-CH2COOH, ili
-OCH2-(CH2)n-N(CH3)-CO-CH2CH2COOH;
n neovisno predstavlja 1 ili 2;
m neovisno predstavlja 1, 2, ili 3; i
k predstavlja 1 ili 2;
ili njegova sol.
2. Spoj prema zahtjevu 1, naznačen time, da je stereocentar od R3 skupina:
2-[(pirolidin-3-karboksilna kiselina)-1-il]-etoksi,
3-[(pirolidin-3-karboksilna kiselina)-1-il]-propoksi,
-O-CH2CH(OH)-CH2NH-CH2COOH, -OCH2CH(OH)-CH2NH-CH2CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2COOH, -OCH2CH(OH)-CH2N(CH3)-CH2CH2COOH,
3-[(azetidin-3-karboksilna kiselina)-1-il]-2-hidroksi-propoksi,
-OCH2-(CH2)n-NH-CH2CH(OH)-CH2OH, -OCH2CH(OH)-CH2NH-CH2CH2OH,
-OCH2CH(OH)-CH2NH-CH(CH2OH)2, i -OCH2CH(OH)-CH2NH-CO-(CH2)nCOOH,
u S-konfiguraciji,
ili sol takvoga spoja.
3. Spoj prema zahtjevu 1, naznačen time, da je stereocentar od R3 skupina:
2-[(pirolidin-3-karboksilna kiselina)-1-il]-etoksi,
3-[(pirolidin-3-karboksilna kiselina)-1-il]-propoksi,
-O-CH2CH(OH)-CH2NH-CH2COOH, -OCH2CH(OH)-CH2NH-CH2CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2CH2COOH,
3-[(azetidin-3-karboksilna kiselina)-1-il]-2-hidroksi-propoksi,
-OCH2-(CH2)n-NH-CH2CH(OH)-CH2OH, -OCH2CH(OH)-CH2NH-CH2CH2OH,
-OCH2CH(OH)-CH2NH-CH(CH2OH)2, i -OCH2CH(OH)-CH2NH-CO-(CH2)nCOOH,
u R-konfiguraciji,
ili sol takvoga spoja.
4. Spoj prema bilo kojem zahtjevu od 1 do 3, naznačen time, da A predstavlja
[image]
gdje zvjezdice označavaju vezu koja je spojena na piridin-skupinu formule (I),
ili sol takvoga spoja.
5. Spoj prema bilo kojem zahtjevu od 1 do 3, naznačen time, da A predstavlja
[image]
gdje zvjezdice označavaju vezu koja je spojena na piridin-skupinu formule (I),
ili sol takvoga spoja.
6. Spoj prema bilo kojem zahtjevu od 1 do 3, naznačen time, da A predstavlja
[image]
ili sol takvoga spoja.
7. Spoj prema bilo kojem zahtjevu od 1 do 6, naznačen time, da R2 predstavlja
metil, i R4 predstavlja etil ili kloro,
ili sol takvoga spoja.
8. Spoj prema bilo kojem zahtjevu od 1 do 6, naznačen time, da R2 predstavlja
metil, i R4 predstavlja etil,
ili sol takvoga spoja.
9. Spoj prema bilo kojem zahtjevu od 1 do 6, naznačen time, da R2 predstavlja
metoksi, i R4 predstavlja kloro,
ili sol takvoga spoja.
10. Spoj prema bilo kojem zahtjevu od 1 do 9, naznačen time, da R3 predstavlja:
-OCH2COOH, -OCH2CH2CH2COOH, -OCH2CONHCH2CH2OH,
-OCH2CH2CH2CONHCH2CH2OH, -OCH2-(CH2)n-NH-(CH2)m-COOH,
-OCH2-(CH2)n-N(CH3)-(CH2)m-COOH,
2-[(azetidin-3-karboksilna kiselina)-1-il]-etoksi,
2-[(pirolidin-3-karboksilna kiselina)-1-il]-etoksi,
3-[(azetidin-3-karboksilna kiselina)-1-il]-propoksi,
-OCH2CH(OH)-CH2NH-CH2COOH, -OCH2CH(OH)-CH2NH-CH2CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2COOH,
3-[(azetidin-3-karboksilna kiselina)-1-il]-2-hidroksi-propoksi,
-OCH2-(CH2)n-NH-CH2CH2OH, -OCH2-(CH2)n-NH-CH(CH2OH)2,
-OCH2-(CH2)n-NH-CH2CH(OH)-CH2OH, -OCH2CH(OH)-CH2NH-CH2CH2OH,
-OCH2CH(OH)-CH2NH-CH(CH2OH)2, -OCH2-(CH2)k-NH-CO-CH2OH,
-OCH2-(CH2)n-NH-CO-CH2COOH, -OCH2-(CH2)n-NH-CO-CH2CH2COOH,
-OCH2CH(OH)-CH2NH-CO-(CH2)nCOOH, -OCH2-(CH2)n-N(CH3)-CO-CH2OH,
-OCH2-(CH2)n-N(CH3)-CO-CH2COOH, ili
-OCH2-(CH2)n-N(CH3)-CO-CH2CH2COOH,
ili sol takvoga spoja.
11. Spoj prema bilo kojem zahtjevu od 1 do 9, naznačen time, da R3 predstavlja:
-OCH2COOH, -OCH2CH2CH2COOH, -OCH2CONHCH2CH2OH,
-OCH2CH2CH2CONHCH2CH2OH, -OCH2-(CH2)n-NH-(CH2)m-COOH,
-OCH2-(CH2)n-N(CH3)-(CH2)m-COOH,
2-[(azetidin-3-karboksilna kiselina)-1-il]-etoksi,
2-[(pirolidin-3-karboksilna kiselina)-1-il]-etoksi,
3-[(azetidin-3-karboksilna kiselina)-1-il]-propoksi,
3-[(pirolidin-3-karboksilna kiselina)-1-il]-propoksi,
-O-CH2CH(OH)-CH2NH-CH2COOH, -OCH2CH(OH)-CH2NH-CH2CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2COOH, -OCH2CH(OH)-CH2N(CH3)-CH2CH2COOH,
3-[(azetidin-3-karboksilna kiselina)-1-il]-2-hidroksi-propoksi,
2-hidroksi-3-[(pirolidin-3-karboksilna kiselina)-1-il]-propoksi,
-OCH2-(CH2)n-NH-CH2CH2OH, -OCH2-(CH2)n-NH-CH(CH2OH)2,
-OCH2-(CH2)n-NH-CH2CH(OH)-CH2OH, -OCH2CH(OH)-CH2NH-CH2CH2OH,
-O-CH2CH(OH)-CH2NH-CH(CH2OH)2, -OCH2-(CH2)k-NH-CO-CH2OH, ili
-OCH2-(CH2)n-N(CH3)-CO-CH2OH,
ili sol takvoga spoja.
12. Spoj prema bilo kojem zahtjevu od 1 do 9, naznačen time, da R3 predstavlja:
OCH2COOH, -OCH2CH2CH2COOH, -OCH2CONHCH2CH2OH,
-OCH2CH2CH2CONHCH2CH2OH, -OCH2-(CH2)n-NH-(CH2)m-COOH,
-OCH2-(CH2)n-N(CH3)-(CH2)m-COOH,
2-[(azetidin-3-karboksilna kiselina)-1-il]-etoksi,
2-[(pirolidin-3-karboksilna kiselina)-1-il]-etoksi,
3-[(azetidin-3-karboksilna kiselina)-1-il]-propoksi,
3-[(pirolidin-3-karboksilna kiselina)-1-il]-propoksi,
-OCH2CH(OH)-CH2N(CH3)-CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2CH2COOH,
3-[(azetidin-3-karboksilna kiselina)-1-il]-2-hidroksi-propoksi,
2-hidroksi-3-[(pirolidin-3-karboksilna kiselina)-1-il]-propoksi,
-OCH2-(CH2)n-NH-CH2CH2OH, -OCH2-(CH2)n-NH-CH(CH2OH)2,
-OCH2CH(OH)-CH2NH-CH2CH2OH, -O-CH2CH(OH)-CH2NH-CH(CH2OH)2,
-OCH2-(CH2)n-NH-CO-CH2COOH, -OCH2-(CH2)n-NH-CO-CH2CH2COOH,
-O-CH2CH(OH)-CH2NH-CO-(CH2)nCOOH, -OCH2-(CH2)n-N(CH3)-CO-CH2COOH, ili
-OCH2-(CH2)n-N(CH3)-CO-CH2CH2COOH,
ili sol takvoga spoja.
13. Spoj prema bilo kojem zahtjevu od 1 do 9, naznačen time, da R3 predstavlja:
-OCH2COOH, -OCH2CH2CH2COOH, -OCH2CONHCH2CH2OH,
-OCH2CH2CH2CONHCH2CH2OH, -OCH2-(CH2)n-NH-(CH2)m-COOH,
-OCH2-(CH2)n-N(CH3)-(CH2)m-COOH,
2-[(azetidin-3-karboksilna kiselina)-1-il]-etoksi,
3-[(azetidin-3-karboksilna kiselina)-1-il]-propoksi,
-OCH2CH(OH)-CH2N(CH3)-CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2CH2COOH,
3-[(azetidin-3-karboksilna kiselina)-1-il]-2-hidroksi-propoksi,
-OCH2-(CH2)n-NH-CH2CH2OH, -OCH2-(CH2)n-NH-CH(CH2OH)2,
-O-CH2CH(OH)-CH2NH-CH2CH2OH, -OCH2CH(OH)-CH2NH-CH(CH2OH)2,
-OCH2-(CH2)k-NH-CO-CH2OH, -OCH2-(CH2)n-NH-CO-CH2COOH,
-OCH2-(CH2)n-NH-CO-CH2CH2COOH,
-OCH2CH(OH)-CH2NH-CO-(CH2)nCOOH,
-OCH2-(CH2)n-N(CH3)-CO-CH2COOH, ili
-OCH2-(CH2)n-N(CH3)-CO-CH2CH2COOH,
ili sol takvoga spoja.
14. Spoj prema bilo kojem zahtjevu od 1 do 9, naznačen time, da R3 predstavlja:
OCH2COOH, -OCH2CH2CH2COOH, -OCH2-(CH2)n-NH-(CH2)m-COOH,
-OCH2-(CH2)n-N(CH3)-(CH2)m-COOH,
2-[(azetidin-3-karboksilna kiselina)-1-il]-etoksi,
3-[(azetidin-3-karboksilna kiselina)-1-il]-propoksi, ili
3-[(azetidin-3-karboksilna kiselina)-1-il]-2-hidroksi-propoksi,
ili sol takvoga spoja.
15. Spoj prema bilo kojem zahtjevu od 1 do 9, naznačen time, da R3 predstavlja:
-OCH2CONHCH2CH2OH, -OCH2CH2CH2CONHCH2CH2OH,
-OCH2CH(OH)-CH2N(CH3)-CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2CH2COOH,
3-[(azetidin-3-karboksilna kiselina)-1-il]-2-hidroksi-propoksi,
-OCH2-(CH2)n-NH-CH2CH2OH, -OCH2-(CH2)n-NH-CH(CH2OH)2,
-O-CH2CH(OH)-CH2NH-CH2CH2OH, ili -O-CH2CH(OH)-CH2NH-CH(CH2OH)2,
ili sol takvoga spoja.
16. Spoj prema bilo kojem zahtjevu od 1 do 14, naznačen time, da
m predstavlja 1 ili 2,
ili sol takvoga spoja.
17. Spoj prema bilo kojem zahtjevu od 1 do 16, naznačen time, da
n predstavlja 1,
ili sol takvoga spoja.
18. Spoj prema zahtjevu 1, naznačen time, da A predstavlja
[image]
gdje zvjezdice označavaju vezu koja je spojena na piridin-skupinu formule (I);
R1 predstavlja ciklopentil;
R2 predstavlja metil, i R4 predstavlja etil ili kloro; ili
R2 predstavlja metoksi, i R4 predstavlja kloro; i
R3 predstavlja:
-OCH2COOH, -OCH2CH2CH2COOH, -OCH2CONHCH2CH2OH,
-OCH2CH2CH2CONHCH2CH2OH, -OCH2-(CH2)1-2-NH-(CH2)1-2-COOH,
-OCH2-CH2-NH-(CH2)3-COOH, -OCH2(CH2)1-2-N(CH3)-(CH2)1-2-COOH,
2-[(azetidin-3-karboksilna kiselina)-1-il]-etoksi,
2-[(pirolidin-3-karboksilna kiselina)-1-il]-etoksi,
3-[(azetidin-3-karboksilna kiselina)-1-il]-propoksi,
-OCH2CH(OH)-CH2NH-CH2COOH, -OCH2CH(OH)-CH2NH-CH2CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2COOH,
3-[(azetidin-3-karboksilna kiselina)-1-il]-2-hidroksi-propoksi,
-OCH2-(CH2)1-2-NH-CH2CH2OH, -OCH2-(CH2)1-2-NH-CH(CH2OH)2,
-OCH2-(CH2)1-2-NH-CH2CH(OH)-CH2OH, -OCH2CH(OH)-CH2NH-CH2CH2OH,
-OCH2CH(OH)-CH2NH-CH(CH2OH)2, -OCH2-(CH2)2-NH-CO-CH2OH,
-OCH2-(CH2)2-NH-CO-CH2COOH, -OCH2-(CH2)2-NH-CO-CH2CH2COOH,
-OCH2CH(OH)-CH2NH-CO-(CH2)1-2COOH, -OCH2-(CH2)2-N(CH3)-CO-CH2OH,
-OCH2-(CH2)2-N(CH3)-CO-CH2COOH, ili
-OCH2-(CH2)2-N(CH3)-CO-CH2CH2COOH,
ili sol takvoga spoja.
19. Spoj prema zahtjevu 1, naznačen time, da R3 predstavlja:
OCH2COOH, -OCH2CH2CH2COOH, -OCH2CONHCH2CH2OH,
-OCH2CH2CH2CONHCH2CH2OH, -OCH2-(CH2)1-2-NH-(CH2)1-2-COOH,
-OCH2-CH2-NH-(CH2)3-COOH, -OCH2-(CH2)1-2-N(CH3)-(CH2)1-2-COOH,
2-[(azetidin-3-karboksilna kiselina)-1-il]-etoksi,
2-[(pirolidin-3-karboksilna kiselina)-1-il]-etoksi,
3-[(azetidin-3-karboksilna kiselina)-1-il]-propoksi,
-OCH2CH(OH)-CH2NH-CH2COOH, -OCH2CH(OH)-CH2NH-CH2CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2COOH,
-OCH2CH(OH)-CH2N(CH3)-CH2CH2COOH,
3-[(azetidin-3-karboksilna kiselina)-1-il]-2-hidroksi-propoksi,
-OCH2-(CH2)1-2-NH-CH2CH2OH, -OCH2-(CH2)1-2-NH-CH(CH2OH)2,
-OCH2-(CH2)1-2-NH-CH2CH(OH)-CH2OH, -OCH2CH(OH)-CH2NH-CH2CH2OH,
-OCH2CH(OH)-CH2NH-CH(CH2OH)2, -OCH2-(CH2)2-NH-CO-CH2OH,
-OCH2-(CH2)1-2-NH-CO-CH2COOH, -OCH2-(CH2)1-2-NH-CO-CH2CH2COOH,
-OCH2CH(OH)-CH2NH-CO-(CH2)1-2COOH, -OCH2-(CH2)2-N(CH3)-CO-CH2OH,
-OCH2-(CH2)2-N(CH3)-CO-CH2COOH, ili
-OCH2-(CH2)2-N(CH3)-CO-CH2CH2COOH,
ili sol takvoga spoja.
20. Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
3-(2-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-etilamino)-propionska kiselina,
1-(2-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-etil)-azetidin-3-karboksilna kiselina,
(S)-1-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-3-(2-hidroksi-etilamino)-propan-2-ol,
2-((S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propilamino)-propan-1,3-diol,
{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-octena kiselina,
4-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-butirna kiselina,
(2-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-etilamino)-octena kiselina,
1-(2-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-etil)-pirolidin-3-karboksilna kiselina,
((S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propilamino)-octena kiselina,
3-((S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propilamino)-propionska kiselina,
[((S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-metil-amino]-octena kiselina,
1-((S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-azetidin-3-karboksilna kiselina,
2-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-N-(2-hidroksi-etil)-acetamid,
N-((S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-malonaminska kiselina,
N-((S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-sukcinaminska kiselina,
[(2-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-etil)-metil-amino]-octena kiselina,
3-[(2-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-etil)-metil-amino]-propionska kiselina,
(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propilamino)-octena kiselina,
3-(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propilamino)-propionska kiselina,
[(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propil)-metil-amino]-octena kiselina,
3-[(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propil)-metil-amino]-propionska kiselina,
1-(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propil)-azetidin-3-karboksilna kiselina,
2-(2-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-etilamino)-etanol,
2-(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propilamino)-etanol,
2-(2-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-etilamino)-propan-1,3-diol,
2-(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propilamino)-propan-1,3-diol,
3-(2-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-etilamino)-propan-1,2-diol,
3-(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propilamino)-propan-1,2-diol,
N-(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propil)-2-hidroksi-acetamid,
N-(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propil)-2-hidroksi-N-metil-acetamid,
N-(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propil)-malonaminska kiselina,
N-(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propil)-sukcinaminska kiselina,
N-(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propil)-N-metil-malonaminska kiselina,
N-(3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propil)-N-metil-sukcinaminska kiselina,
4-{2-kloro-4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-6-metoksi-fenoksi}-butirna kiselina,
4-{2-kloro-4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-6-metoksi-fenoksi}-N-(2-hidroksi-etil)-butiramid,
3-(2-{2-kloro-4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-6-metoksi-fenoksi}-etil-amino)-propionska kiselina,
N-(3-{2-kloro-4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-6-metoksi-fenoksi}-propil)-2-hidroksi-acetamid,
4-((2-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-2-etil-6-metilfenoksi)etil)amino)butanoinska kiselina, i
4-(2-kloro-4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-6-metilfenoksi)butanoinska kiselina,
ili sol takvoga spoja.
21. Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
2-(2-kloro-4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-6-metilfenoksi)octena kiselina,
2-(2-kloro-4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-6-metil-fenoksi)-N-(2-hidroksietil)acetamid,
3-((2-(2-kloro-4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-6-metilfenoksi)etil)amino)propanoinska kiselina,
1-(2-(2-kloro-4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-6-metilfenoksi)etil)azetidin-3-karboksilna kiselina,
2-((2-(2-kloro-4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-6-metilfenoksi)etil)amino)etanol,
4-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-2-etil-6-metilfenoksi)-N-(2-hidroksietil)butanamid,
(S)-3-((3-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-2-etil-6-metilfenoksi)-2-hidroksipropil)(metil)amino)propanoinska kiselina,
(R)-3-((3-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-2-etil-6-metilfenoksi)-2-hidroksipropil)(metil)amino)propanoinska kiselina,
3-((2-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-2-etil-6-metilfenoksi)etil)amino)-3-oksopropanoinska kiselina,
4-((2-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-2-etil-6-metilfenoksi)etil)amino)-4-oksobutanoinska kiselina,
2-((2-(2-kloro-4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-6-metoksifenoksi)etil)amino)octena kiselina,
1-(2-(2-kloro-4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-6-metoksifenoksi)etil)azetidin-3-karboksilna kiselina,
2-(4-(3-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-5-il)-2-etil-6-metilfenoksi)octena kiselina,
4-(4-(3-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-5-il)-2-etil-6-metilfenoksi)butanoinska kiselina,
2-((2-(4-(3-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-5-il)-2-etil-6-metilfenoksi)etil)amino)octena kiselina,
2-((2-(4-(3-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-5-il)-2-etil-6-metilfenoksi)etil)(metil)amino)octena kiselina,
3-((2-(4-(3-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-5-il)-2-etil-6-metilfenoksi)etil)amino)propanoinska kiselina,
1-(2-(4-(3-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-5-il)-2-etil-6-metilfenoksi)etil)azetidin-3-karboksilna kiselina,
2-((3-(4-(3-(2-ciklopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-5-il)-2-etil-6-metilfenoksi)propil)amino)octena kiselina,
2-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,3,4-oksadiazol-2-il)-2-etil-6-metilfenoksi)octena kiselina,
4-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,3,4-oksadiazol-2-il)-2-etil-6-metilfenoksi)butanoinska kiselina,
3-((2-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,3,4-oksadiazol-2-il)-2-etil-6-metilfenoksi)etil)amino)propanoinska kiselina,
1-(2-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,3,4-oksadiazol-2-il)-2-etil-6-metilfenoksi)etil)azetidin-3-karboksilna kiselina,
(S)-1-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,3,4-oksadiazol-2-il)-2-etil-6-metilfenoksi)-3-((2-hidroksietil)amino)propan-2-ol,
(S)-2-((3-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,3,4-oksadiazol-2-il)-2-etil-6-metilfenoksi)-2-hidroksipropil)amino)propan-1,3-diol, i
(S)-4-((3-(4-(5-(2-ciklopentil-6-metoksipiridin-4-il)-1,3,4-oksadiazol-2-il)-2-etil-6-metilfenoksi)-2-hidroksipropil)amino)-4-oksobutanoinska kiselina,
ili sol takvoga spoja.
22. Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem zahtjevu od 1 do 21, ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač.
23. Spoj prema bilo kojem zahtjevu od 1 do 21, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski sastav prema zahtjevu 22, naznačen time, da se upotrebljava kao lijek.
24. Spoj prema bilo kojem zahtjevu od 1 do 21, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava u prevenciji ili liječenju bolesti ili poremećaja odabranih iz skupine koju čine:
odbacivanje transplantiranih organa kao što su bubreg, jetra, srce, pluća, gušterača, rožnica i koža; usadak protiv stanice domaćina, što je posljedica transplantacije matičnih stanica; autoimuni sindromi koji uključuju reumatoidni artritis, multiplu sklerozu,
upalnu bolest crijeva kao što je Crohnova bolest i ulcerativni kolitis, psorijazu, psorijatički artritis, tiroiditis kao što je Hashimotoov tiroiditis, uveo-retinitis; atopične bolesti kao što su rinitis, konjunktivitis, dermatitis; astma; dijabetes tipa I; post-infekcijske autoimune bolesti koje uključuju reumatsku groznicu i post-infekcijski glomerulonefritis; čvrsti rak i tumorske metastaze.
25. Spoj prema bilo kojem zahtjevu od 1 do 21, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava u prevenciji ili liječenju bolesti ili poremećaja odabranih iz skupine koju čine:
odbacivanje transplantiranih organa kao što su bubreg, jetra, srce i pluća; usadak protiv
stanice domaćina, što je posljedica transplantacije matičnih stanica; autoimuni sindromi koji su odabrani od reumatoidnog artritisa, multiple skleroze, psorijaze, psorijatičkog artritisa, Crohnove bolesti, i Hashimotoovog tiroiditisa; te atopični dermatitis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2011050241 | 2011-01-19 | ||
EP12704125.9A EP2665720B1 (en) | 2011-01-19 | 2012-01-18 | 2-methoxy-pyridin-4-yl derivatives |
PCT/IB2012/050241 WO2012098505A1 (en) | 2011-01-19 | 2012-01-18 | 2-methoxy-pyridin-4-yl derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150919T1 true HRP20150919T1 (hr) | 2015-09-25 |
Family
ID=45607310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150919TT HRP20150919T1 (hr) | 2011-01-19 | 2015-09-02 | Derivati 2-metoksi-piridin-4-ila |
Country Status (28)
Country | Link |
---|---|
US (1) | US9133179B2 (hr) |
EP (1) | EP2665720B1 (hr) |
JP (1) | JP5859570B2 (hr) |
KR (1) | KR101869120B1 (hr) |
CN (1) | CN103313981B (hr) |
AR (1) | AR084883A1 (hr) |
AU (1) | AU2012208325B2 (hr) |
BR (1) | BR112013017923B1 (hr) |
CA (1) | CA2818470C (hr) |
CL (1) | CL2013002056A1 (hr) |
CY (1) | CY1116657T1 (hr) |
DK (1) | DK2665720T3 (hr) |
ES (1) | ES2544086T3 (hr) |
HK (1) | HK1191645A1 (hr) |
HR (1) | HRP20150919T1 (hr) |
HU (1) | HUE026012T2 (hr) |
IL (1) | IL227509A0 (hr) |
MA (1) | MA34910B1 (hr) |
MX (1) | MX350009B (hr) |
MY (1) | MY163185A (hr) |
PL (1) | PL2665720T3 (hr) |
PT (1) | PT2665720E (hr) |
SG (1) | SG191742A1 (hr) |
SI (1) | SI2665720T1 (hr) |
TW (1) | TWI546300B (hr) |
UA (1) | UA109804C2 (hr) |
WO (1) | WO2012098505A1 (hr) |
ZA (1) | ZA201306193B (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102212975B1 (ko) | 2013-03-15 | 2021-02-05 | 이도르시아 파마슈티컬스 리미티드 | 피리딘-4-일 유도체 |
EP2990055B1 (en) | 2013-04-26 | 2019-06-05 | Kyoto University | Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it |
CN105760707B (zh) * | 2014-12-18 | 2018-07-31 | 中国科学院大连化学物理研究所 | 细胞基因翻译过程建模方法 |
CN114573574A (zh) | 2015-05-20 | 2022-06-03 | 爱杜西亚药品有限公司 | 一种化合物的结晶形式 |
CN107382965A (zh) * | 2017-08-14 | 2017-11-24 | 河南科技大学第附属医院 | 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3647809A (en) | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
CA2051494C (en) | 1990-09-20 | 2006-03-14 | Robert J. Dinerstein | 1-aryl-3-pyridinyl-2-propene-1-ones as calcium uptake inhibitors |
DE4429465A1 (de) | 1994-08-19 | 1996-02-22 | Bayer Ag | Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde |
WO1999046277A1 (en) | 1998-03-09 | 1999-09-16 | Smithkline Beecham Corporation | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE |
DE19904389A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
DK1210344T3 (da) | 1999-08-19 | 2006-03-06 | Nps Pharma Inc | Heteropolycykliske forbindelser og anvendelser deraf som metabotrope glutamatreceptorantagonister |
NZ527691A (en) | 2001-02-21 | 2007-01-26 | Nps Pharma Inc | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US7479504B2 (en) | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
WO2003062248A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
CA2488117A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
DE10237883A1 (de) | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
US20060252741A1 (en) | 2003-05-15 | 2006-11-09 | Colandrea Vincent J | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
WO2005014525A2 (en) | 2003-08-12 | 2005-02-17 | Mitsubishi Pharma Corporation | Bi-aryl compound having immunosuppressive activity |
CN1859908A (zh) | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5-芳基、杂芳基或环烷基取代的-1,2,4-噁二唑类化合物 |
JP4773972B2 (ja) | 2003-12-17 | 2011-09-14 | メルク・シャープ・エンド・ドーム・コーポレイション | S1P(Edg)受容体作働薬としての(3,4−ジ置換)プロパンカルボン酸 |
US8022063B2 (en) | 2004-05-29 | 2011-09-20 | 7Tm Pharma A/S | CRTH2 receptor ligands for medicinal uses |
WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
WO2006047195A2 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
PL1826197T3 (pl) | 2004-12-13 | 2012-06-29 | Ono Pharmaceutical Co | Pochodna kwasu aminokarboksylowego i jej zastosowanie lecznicze |
RU2404178C2 (ru) | 2005-03-23 | 2010-11-20 | Актелион Фармасьютиклз Лтд | Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1 |
JP5047941B2 (ja) | 2005-03-23 | 2012-10-10 | アクテリオン ファーマシューティカルズ リミテッド | 免疫調節物質としての水素付加されたベンゾ(c)チオフェン誘導体 |
CN101180050B (zh) | 2005-03-23 | 2011-07-27 | 埃科特莱茵药品有限公司 | 作为鞘氨醇-1-磷酸盐-1受体激动剂的新颖噻吩衍生物 |
RU2007140903A (ru) | 2005-04-05 | 2009-05-20 | Фармакопия, Инк. (Us) | Производные пурина и имидазопиридина для иммуносупрессии |
CN101203512A (zh) | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
AU2006239418A1 (en) | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
AU2006256968A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | Polycyclic oxadiazoles or I soxazoles and their use as SIP receptor ligands |
WO2006135694A2 (en) | 2005-06-10 | 2006-12-21 | Acadia Pharmaceuticals Inc. | Uii-modulating compounds and their use |
AU2006260573A1 (en) | 2005-06-24 | 2006-12-28 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
US20090054491A1 (en) | 2005-06-28 | 2009-02-26 | Astrazeneca Ab | Use |
AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
TWI404706B (zh) * | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
EP1979345B1 (en) | 2006-01-24 | 2009-11-04 | Actelion Pharmaceuticals Ltd. | Novel pyridine derivatives |
GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
EP1991535A1 (en) | 2006-02-21 | 2008-11-19 | University Of Virginia Patent Foundation | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as sip receptor agonists |
WO2007132307A1 (en) | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
AR061841A1 (es) | 2006-09-07 | 2008-09-24 | Actelion Pharmaceuticals Ltd | Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores. |
AU2007292993B2 (en) * | 2006-09-07 | 2013-01-24 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
CA2661315C (en) | 2006-09-08 | 2015-11-24 | Actelion Pharmaceuticals Ltd | Pyridin-3-yl derivatives as immunomodulating agents |
RU2442780C2 (ru) | 2006-09-21 | 2012-02-20 | Актелион Фармасьютиклз Лтд | Фенильные производные и их применение в качестве иммуномодуляторов |
BRPI0717656A2 (pt) | 2006-09-29 | 2014-04-29 | Novartis Ag | Derivados de diaril oxadiazol |
JP2008120794A (ja) | 2006-10-16 | 2008-05-29 | Daiichi Sankyo Co Ltd | ヘテロ環化合物を含有する医薬組成物 |
US20110207704A1 (en) | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
AU2007334436A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
WO2008091967A1 (en) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
SI2195311T1 (sl) | 2007-08-17 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Derivati piridina kot modulatorji receptorja s1p1/edg1 |
CA2696829C (en) | 2007-10-04 | 2017-07-04 | Merck Serono S.A. | Oxadiazole diaryl compounds |
AU2008306885B2 (en) | 2007-10-04 | 2013-12-05 | Merck Serono S.A. | Oxadiazole derivatives |
AU2008320374A1 (en) | 2007-11-01 | 2009-05-07 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
WO2009060278A1 (en) | 2007-11-08 | 2009-05-14 | Pfizer Inc. | Cyclobutyl carboxylic acid derivatives |
RU2010128006A (ru) | 2007-12-10 | 2012-01-20 | Актелион Фармасьютиклз Лтд (Ch) | Производные тиофена в качестве агонистов sipi/edgi |
EP2222668B1 (en) * | 2007-12-18 | 2011-11-02 | Arena Pharmaceuticals, Inc. | Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
ES2389042T3 (es) | 2008-03-06 | 2012-10-22 | Actelion Pharmaceuticals Ltd. | Compuestos de piridina |
JP2011513385A (ja) | 2008-03-06 | 2011-04-28 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピリミジン−ピリジン誘導体 |
SI2252609T1 (sl) | 2008-03-07 | 2013-07-31 | Actelion Pharmaceuticals Ltd. | Derivati piridin-2-ila kot imunomodulacijska sredstva |
US8410151B2 (en) * | 2008-03-07 | 2013-04-02 | Actelion Pharmaceuticals Ltd | Aminomethyl benzene derivatives |
NZ589617A (en) | 2008-05-14 | 2012-06-29 | Scripps Research Inst | 3-(Inden-4-yl)-5-(phenyl)-1,2,4-oxadiazole and 3-(tetralin-5-yl)-5-(phenyl)-1,2,4-oxadiazole derivatives |
JP2012530728A (ja) | 2009-06-26 | 2012-12-06 | グラクソ グループ リミテッド | スフィンゴシン1−リン酸受容体アゴニストとして用いられる5員ヘテロアリール誘導体 |
TWI410421B (zh) * | 2009-07-16 | 2013-10-01 | Actelion Pharmaceuticals Ltd | 吡啶-4-基衍生物 |
-
2012
- 2012-01-18 AU AU2012208325A patent/AU2012208325B2/en active Active
- 2012-01-18 HU HUE12704125A patent/HUE026012T2/en unknown
- 2012-01-18 US US13/980,764 patent/US9133179B2/en active Active
- 2012-01-18 MA MA36184A patent/MA34910B1/fr unknown
- 2012-01-18 MX MX2013007726A patent/MX350009B/es active IP Right Grant
- 2012-01-18 AR ARP120100163A patent/AR084883A1/es unknown
- 2012-01-18 BR BR112013017923-6A patent/BR112013017923B1/pt active IP Right Grant
- 2012-01-18 ES ES12704125.9T patent/ES2544086T3/es active Active
- 2012-01-18 TW TW101101997A patent/TWI546300B/zh active
- 2012-01-18 SI SI201230254T patent/SI2665720T1/sl unknown
- 2012-01-18 CN CN201280005493.7A patent/CN103313981B/zh active Active
- 2012-01-18 MY MYPI2013701260A patent/MY163185A/en unknown
- 2012-01-18 CA CA2818470A patent/CA2818470C/en active Active
- 2012-01-18 PL PL12704125T patent/PL2665720T3/pl unknown
- 2012-01-18 PT PT127041259T patent/PT2665720E/pt unknown
- 2012-01-18 EP EP12704125.9A patent/EP2665720B1/en active Active
- 2012-01-18 WO PCT/IB2012/050241 patent/WO2012098505A1/en active Application Filing
- 2012-01-18 KR KR1020137020321A patent/KR101869120B1/ko active IP Right Grant
- 2012-01-18 SG SG2013047212A patent/SG191742A1/en unknown
- 2012-01-18 JP JP2013549917A patent/JP5859570B2/ja active Active
- 2012-01-18 DK DK12704125.9T patent/DK2665720T3/en active
- 2012-01-18 UA UAA201309611A patent/UA109804C2/ru unknown
-
2013
- 2013-07-17 CL CL2013002056A patent/CL2013002056A1/es unknown
- 2013-07-17 IL IL227509A patent/IL227509A0/en active IP Right Grant
- 2013-08-16 ZA ZA2013/06193A patent/ZA201306193B/en unknown
-
2014
- 2014-05-23 HK HK14104850.5A patent/HK1191645A1/xx not_active IP Right Cessation
-
2015
- 2015-08-28 CY CY20151100762T patent/CY1116657T1/el unknown
- 2015-09-02 HR HRP20150919TT patent/HRP20150919T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150919T1 (hr) | Derivati 2-metoksi-piridin-4-ila | |
HRP20130181T1 (hr) | Derivati piridin-4-ila kao sredstva imunomodulacije | |
HRP20130180T1 (hr) | Derivati piridin-3-ila kao sredstva imunomodulacije | |
HRP20140335T1 (hr) | Derivati amino-piridina kao agonisti s1p1/edg1-receptora | |
HRP20140098T1 (hr) | Derivati piridin-4-ila kao agonisti s1p1/edg1 | |
JP2009523165A5 (hr) | ||
HRP20160450T1 (hr) | Novi inhibitori reduktaze s-nitrozoglutationa | |
RU2010121969A (ru) | Новые производные пиримидина | |
RU2437877C2 (ru) | Новые производные тиофена в качестве агонистов рецептора s1p1/edg1 | |
JP4471842B2 (ja) | アミド化合物および該化合物を用いる方法 | |
US20200190019A1 (en) | Ppar agonists | |
JP2013542937A5 (hr) | ||
US8008292B2 (en) | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | |
HRP20120962T1 (hr) | Derivati tiofena kao agonisti s1p1/edg1 receptora | |
ES2433466T3 (es) | Compuestos, composiciones farmacéuticas y métodos para su uso en el tratamiento de trastornos metabólicos | |
JP2007519619A5 (hr) | ||
JP2004534824A5 (hr) | ||
ES2617221T3 (es) | Derivados de 3-(2-aril-cicloalquenilmetil)-oxazolidin-2-ona como inhibidores de la proteína de transferencia de ésteres de colesterol (CETP) | |
PT888317E (pt) | Derivados do acido 4-hidroxi-fenilalcanoico substituido com actividade agonista para ppar-gama | |
JP2008511586A5 (hr) | ||
JP2014530900A5 (hr) | ||
RU2006142746A (ru) | Индолилпроизводные в качестве модуляторов печеночного х-рецептора | |
JP2010513397A5 (hr) | ||
HRP20161702T1 (hr) | Novi derivati pirazina | |
CN1946391A (zh) | 包含α-2-δ配体的组合 |